Sio Gene could be a canary in the coalmine for gene therapy

Once, pivoting to gene therapy seemed like a handy method of reinvention for Sio Gene Therapies, formerly known as Axovant. Now, involvement in the sector seems more like a poisoned chalice. Many gene therapy companies have struggled on the stock markets lately, but Sio has become the first of its peers to throw in the towel, saying yesterday that it was ceasing development of its two remaining assets, AXO-AAV-GM1 and AXO-AAV-GM2, and reviewing strategic alternatives.